UCB-NK (Oncoinsight)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameUCB-NK (Oncoinsight)

Drug Alias Nameumbilical cord blood-derived natural killer cell therapy (Oncoinsight)

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionNatural killer cells stimulantsImmunostimulants

TargetsUpdating

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesOncoinsight Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOncoinsight Co Ltd

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A